NCT02040194View on ClinicalTrials.gov

AM-101 in the Treatment of Acute Tinnitus 3

PHASE3CompletedINTERVENTIONAL

Enrollment

893

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 28, 2017

Study Completion Date

December 28, 2017

Conditions

Tinnitus

Interventions

DRUG

AM-101

AM-101 gel for intratympanic injection

DRUG

Placebo

Placebo gel for intratympanic injection

Trial Locations (1)

Unknown

Please check the study webpage below for a study site list, Munich

Sponsors

Lead Sponsor

Auris Medical AG

All Listed Sponsors

lead

Auris Medical AG

INDUSTRY

NCT02040194 - AM-101 in the Treatment of Acute Tinnitus 3 | Biotech Hunter | Biotech Hunter